NVNO enVVeno Medical Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1661053 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY29.2%
TTM EPS YoY67.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-67.1%
ROA-60.0%
ROIC (approx.)-61.4%
Asset turnover—
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.86x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $9.98M | $12.25M |
| SG&A expense | $10.92M | $11.58M |
| Operating income | -$20.90M | -$23.83M |
| Pretax income | -$19.47M | -$21.82M |
| Net income | -$19.47M | -$21.82M |
| EBITDA | -$20.76M | -$23.64M |
| EPS (basic) | -33.06 | -44.53 |
| EPS (diluted) | -33.06 | -44.53 |
| Weighted avg. shares (diluted) | 589,000 | 490,000 |
| Balance sheet | ||
| Cash & equivalents | $3.06M | $1.75M |
| Short-term investments | $25.15M | $41.40M |
| Current assets | $28.83M | $43.73M |
| PP&E, net | $51,000 | $182,000 |
| Total assets | $29.56M | $44.95M |
| Current liabilities | $2.12M | $2.10M |
| Total liabilities | $2.43M | $2.79M |
| Shareholders' equity | $27.13M | $42.16M |
| Shares outstanding | 656,000 | 501,000 |
| Cash flow statement | ||
| Operating cash flow | -$15.57M | -$16.84M |
| Capital expenditure | $5,000 | $37,000 |
| Free cash flow | -$15.57M | -$16.88M |
| Investing cash flow | $15.86M | $1.33M |
| Financing cash flow | $1.02M | $13.64M |
| Depreciation & amortization | $136,000 | $189,000 |
| Stock-based compensation | $3.42M | $4.14M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.